Proposals are expected to advance the knowledge specifically on COVID-19 and more widely on the coronavirus family with the aim of contributing to an efficient patient management and/or public health preparedness and response to current and future outbreaks of coronavirus infection.
It is crucial to rapidly gain a better understanding of the newly identified virus, especially in relation to potential clinical and public health measures that can be put to immediate use to improve patients’ health and/or contain its spread.
Collaboration of private companies, academia, international organisations, public bodies etc. has the potential to accelerate the development of therapeutics and diagnostics to tackle this current and future outbreaks.
The actions resulting from this call will contribute to the pan-European efforts responding to this Public Health Emergency.
Considering that this is a newly identified virus, the scope of this topic remains broad and must address at least one of the following objectives:
1. Development of therapeutics to address a rapid response towards the current COVID-19 outbreak: relevant “clinical ready”-assets include approved therapies or compounds in development, which could be repurposed for use in treating patients with the coronavirus;
2. Development of therapeutics to address the current and/or future coronaviruses outbreaks: identification of new potential assets and approaches that could be utilised including preventive strategies and combination approaches and could also address potential resistance. This may also include optimisation of promising treatments used in rapid response (e.g. reformulation);
3. Development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies, to allow for fast case detection and surveillance;
4. Development of fast and reliable detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection. This can be achieved through point of care (POC) testing or centralised testing.
Preventive vaccines are specifically excluded from the scope of the Call.
Each proposal must include at least one of the following key deliverables:
a) antivirals as well as other types of therapeutics to be used in the current outbreak, including preventive and symptomatic treatments;
b) novel therapeutics including combination treatments to ensure appropriate treatment for current and/or future outbreaks and/or prevent resistance;
d) In the context of achieving the above deliverables, i.e. development of therapeutics and diagnostics, it is recognised that studies related to the understanding of the mechanism of action will generate new knowledge on the virology, immunology and pathogenesis of the coronavirus, and that new analytical technologies and reagents may be developed.
In accordance with the Horizon 2020 Rules for Participation, in order to be eligible, a proposal must be made by a consortium of at least three independent legal entities, each established in a different EU Member State or associated country.
Applicant consortia will be competing for the maximum total financial contribution from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) up to EUR 45 000 000.
All grants awarded under this Call will be complementary grants.
Utilize This Offer
Any proposal must be made by a consortium of at least three independent legal entities, each established in a different EU Member State or associated country.
Submission deadline: 31 March 2020 at 17:00:00 Brussels time.
For more information, please visit https://tinyurl.com/uyha45r